Here are six drug and medical device companies that made headlines in the past week.
1. Primus Pharma halts production, marketing of Limbrel in response to FDA safety concerns
Scottsdale, Ariz.-based Primus Pharmaceuticals took its osteoarthritis treatment Limbrel off the market at the FDA's request.
2. PharMEDium recalls 25k drug units due to sterility issues: 4 things to know
PharMEDium is recalling 55 lots of various drug products due to a lack of sterility assurance.
3. Allergan to cut more than 1k jobs: 3 things to know
Allergan will eliminate more than 1,000 positions in anticipation of generic competition surrounding its popular dry-eye drug Restasis.
4. First gene therapy drug priced lower than expected at $850k
Spark Therapeutics' Luxturna, the first gene therapy to gain FDA approval for the treatment of a rare, inherited retinal disease that can lead to blindness, will cost patients $850,000 for a one-time treatment, or $425,000 per eye.
5. Microsoft partners with Adaptive Biotechnologies to 'decode' immune systems with AI
Microsoft has joined forces with Adaptive Biotechnologies, a Seattle-based biotech company, to map the human immune system, according to a Jan. 4 Microsoft blog post by Peter Lee, PhD, the company's corporate vice president of artificial intelligence and research.
6. FDA issues recall of J&J's heart device over faulty valve
The FDA issued a Class I recall Jan. 2 for a heart device manufactured and distributed by a unit of Johnson & Johnson — citing a faulty valve.
More articles on supply chain:
Celgene to acquire Impact Biomedicines for up to $7B
AdvaMed TV ads call on Congress to end device tax: 4 things to know
FDA OKs expanded use of Amgen's bone drug: 4 things to know